

AMENDMENT
US APPLN. NO. 10/626,138

Amendments to claims:

Listing of Claims as amended:

1. (Currently Amended) A method for the treatment ~~or prevention~~ of heart failure, which comprises the administration to a patient in need thereof of a pharmaceutical composition comprising cilobradine or a pharmaceutically acceptable salt thereof, together with a pharmaceutically suitable carrier.
- 2-3 Cancelled.
4. (Original) The method of claim 1 wherein the galenical formulation of the pharmaceutical composition is a tablet, a drinking solution, a capsule, a suppository or an injectable formulation.
5. (Original) The method of claim 4 wherein the galenical formulation of the pharmaceutical composition is a tablet.
6. (Original) The method of claim 4 wherein the galenical formulation of the pharmaceutical composition is a drinking solution.
7. (Currently Amended) The method of claim 1 wherein the pharmaceutical composition is administered following a single daily ~~or multiple stage daily~~ application scheme.
8. (Original) The method of claim 7 wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.01 and 20 mg/kg body weight.

AMENDMENT
US APPLN. NO. 10/626,138

9. (Original) The method of claim 7 wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.05 and 5 mg/kg body weight.
10. (Original) The method of claim 7 wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.1 and 2.5 mg/kg body weight.
11. (Original) The method according to claim 7 wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.1 and 1 mg/kg body weight.
12. (Original) The method of claim 7 wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.1 and 0.75 mg/kg body weight.
13. (Currently amended) The method of claim 1 wherein the treatment or prevention of heart failure is performed in combination with other therapeutic agents for the treatment or prevention of heart failure.
14. (Original) The method of claim 13 wherein said therapeutic agents include diuretics, cardiac glycosides, ACE inhibitors, ARBs, vasodilators, beta blockers or inotropes.
15. (New) The method of claim 1 wherein the pharmaceutical composition is administered multiple times daily.
16. (New) The method of claim 15 wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.01 and 20 mg/kg body weight.
17. (New) The method of claim 15 wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.05 and 5 mg/kg body weight.

AMENDMENT
US APPLN. NO. 10/626,138

18. (New) The method of claim 15 wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.1 and 2.5 mg/kg body weight.
19. (New) The method according to claim 15 wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.1 and 1 mg/kg body weight.
20. (New) The method of claim 15 wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.1 and 0.75 mg/kg body weight.